Outlook Therapeutics at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference
Nov 13, 2021 at 9:17 AM EST
Safety and Efficacy Results of ONS-5010, an Ophthalmic Bevacizumab, Phase 3 Pivotal Study of Monthly Intravitreal ONS-5010 in Subjects with Wet AMD (NORSE TWO)
Presenter: Firas M. Rahhal, MD
Session: Section X: Late Breaking Developments, Part II
Date and time: Saturday, November 13, 2021, at 9:17 AM EDT
